Image de couverture de livre

Editorial: Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Prior to Liver Transplantation—Current Evidence and Future Directions. Authors' reply

Fuente: Wiley Open Access

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	L. Aceituno, A. Vogel, G. Sapisochin
Format:	Artículo Open Access
Publié:	Wiley 2026
Sujets:	Alimentary Pharmacology & Therapeutics
Accès en ligne:	Acceder al recurso
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Editorial: Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Prior to Liver Transplantation—Current Evidence and Future Directions
par: Mohammad Saeid Rezaee‐Zavareh, et autres
Publié: (2026)

Editorial: Immune Checkpoint Inhibitors and HBV Reactivation in Liver Cancer—Reassurance With Vigilance. Authors' Reply
par: Terry Cheuk‐Fung Yip, et autres
Publié: (2025)

Editorial: Immune Checkpoint Inhibitors and HBV Reactivation in Liver Cancer—Reassurance With Vigilance
par: Romeo Kuo‐Cheng Wu, et autres
Publié: (2025)

Editorial: Checkpoint Inhibitor‐Induced Liver Injury—Time to Abandon CTCAE?
par: Kelly Torosian, et autres
Publié: (2024)

Hepatic Events During Immune Checkpoint Inhibitor Treatment Between Liver and Non‐Liver Malignancies in Hepatitis B Endemic Areas
par: Yi‐Ping Hung, et autres
Publié: (2024)

Editorial: Quantity is important! Authors' reply
par: Marika Rudler, et autres
Publié: (2024)

Editorial: Genotyping for Hepatocellular Carcinoma Risk Stratification in the General Population. Authors' Reply
par: Daniel Q. Huang, et autres
Publié: (2026)

Letter: Liver Transplantation Outcomes for Alcohol‐Associated Liver Disease—Commentary on an Individual Patient Data Meta‐Analysis and Future Research Directions. Authors' Reply
par: Ryan Yanzhe Lim, et autres
Publié: (2026)

Editorial: Direct‐Acting Agents and Risk of Hepatocellular Carcinoma—The End of Controversy
par: Vincent Haghnejad, et autres
Publié: (2025)

Editorial: Another brick in the CDST wall: Authors' reply
par: Kyuwon Kim, et autres
Publié: (2024)

Editorial: Crystalising the burden of steatotic liver disease—Authors' reply
par: Carolin V. Schneider, et autres
Publié: (2024)

Editorial: Recompensation in PBC is good. But is it good enough? Authors' reply
par: Benedikt Silvester Hofer, et autres
Publié: (2024)

Editorial: The microbiome and gastric mucosal protection in aspirin users—Authors' reply
par: Nina Løn, et autres
Publié: (2024)

Editorial: Emulsifiers and thickeners in our food—Do they alter gut permeability? Authors' reply
par: Jessica A. Fitzpatrick, et autres
Publié: (2024)

Editorial: Variceal Bleeding in Patients Receiving Atezolizumab–Bevacizumab for Hepatocellular Carcinoma—Don't Ignore the Risk Factors! Authors' Reply
par: Jonggi Choi
Publié: (2025)

Letter: Beyond Association—Operationalising PRS ‐5 for Hepatocellular Carcinoma Surveillance. Authors' Reply
par: Yu‐Sheng Lin, et autres
Publié: (2026)

Letter on ‘Inherited Genetic Risk of Liver Fibrosis in Lean Versus Nonlean Metabolic Dysfunction‐Associated Steatotic Liver Disease ( MASLD )’; Authors’ reply
par: Kaleb Tesfai, et autres
Publié: (2026)

Editorial: Can we predict or not predict response to hypnotherapy? That is the question. Authors' reply
par: Dipesh H. Vasant, et autres
Publié: (2024)

Editorial: Revisit the causes and long‐term outcomes in cirrhosis patients—Authors' reply
par: Linda Henry, et autres
Publié: (2024)

Editorial: Sonographic assessment of colonic content—A new tool for constipation? Authors' reply
par: R. M. Mathias, et autres
Publié: (2024)

Editorial: Predicting Hepatocellular Carcinoma Development in Chronic Hepatitis B Patients With Metabolic Dysfunction—Do Existing Scores Clear the Bar? Authors' Reply
par: Lesley A. Patmore, et autres
Publié: (2025)

Editorial: Predicting Hepatocellular Cancer in Clinical Practice. Authors' Reply
par: Shuaibing Ying, et autres
Publié: (2026)

Editorial: High Baseline ALT Level Confers Risk of Hepatic Adverse Events During Immune Checkpoint Inhibitors Treatment: A Call for Caution
par: Ze‐Hua Zhao, et autres
Publié: (2025)

Letter: Tumour Burden Score for Predicting Extrahepatic Metastasis in Hepatocellular Carcinoma After Curative Resection. Authors' Reply
par: Elisa Pinto, et autres
Publié: (2026)

Letter: Liver Transplantation Outcomes for Alcohol‐Associated Liver Disease—Commentary on an Individual Patient Data Meta‐Analysis and Future Research Directions
par: Xinglin Li, et autres
Publié: (2026)

Editorial: Redefining Safety in Post‐Liver Transplant IBD —Why Therapeutic Effectiveness Is the Ultimate Shield. Authors' Reply
par: Simone Chin, et autres
Publié: (2025)

Editorial: Genetics for non‐invasive risk stratification—Finding the needle in the haystack? Authors' reply
par: Lana Bridi, et autres
Publié: (2024)

Editorial: Mortality in immune‐mediated inflammatory diseases during early adulthood—Authors' reply
par: Mikkel Malham, et autres
Publié: (2024)

Editorial: High qHBsAg—Is it a good or bad signal? Authors' reply
par: Hsin‐Che Lin, et autres
Publié: (2024)

Editorial: Hepatitis C virus eradication improves skeletal muscle mass—Authors' reply
par: Marta Paula Pereira Coelho, et autres
Publié: (2024)

Editorial: Infliximab induction therapy in paediatric Crohn's disease — A cost‐effective strategy? Authors' reply
par: Stephanie A. Vuijk, et autres
Publié: (2024)

Letter: Irritable bowel syndrome and antibiotics—Authors' reply
par: Kyle Staller, et autres
Publié: (2024)

Letter: Methodological Considerations in Interpreting Polygenic Risk Scores for Hepatocellular Carcinoma After SVR . Authors' Reply
par: Yu‐Sheng Lin, et autres
Publié: (2026)

Editorial: Mucosal healing with steroids—Once upon a time in ulcerative colitis. Authors' reply
par: Tomohiro Fukuda, et autres
Publié: (2024)

Editorial: The tsunami of steatotic liver disease in India, the Asia‐Pacific region and the world—Authors' reply
par: Manya Prasad, et autres
Publié: (2024)

Editorial: Sequencing rescue therapy for acute severe ulcerative colitis—Ready for revision? Authors' reply
par: María José García, et autres
Publié: (2024)

Editorial: Eosinophilic oesophagitis coming of age—Increasing frequency and wider age range—Authors' reply
par: Akshatha Kiran, et autres
Publié: (2024)

Editorial: Reading the cholate—A new gateway to portal hypertension and oesophageal varices: Authors' reply
par: Tarek Hassanein, et autres
Publié: (2024)

Editorial: Unravelling real‐world impact of second‐line therapies in primary biliary cholangitis—Time to change our targets? Authors' reply
par: C. M. Fernández‐Rodríguez, et autres
Publié: (2024)

Letter: Prospective Individualised Validation of the GES in Predicting Hepatocellular Carcinoma—A ‘Precision Medicine’ Study: Authors' Reply
par: Gamal Shiha, et autres
Publié: (2025)